Claims Study Shows Better Glycemic Control, Less Switching With Canagliflozin Than Dapagliflozin | Latest News RSS feed
Claims Study Shows Better Glycemic Control, Less Switching With Canagliflozin Than Dapagliflozin - Latest News
Johnson & Johnson : Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 ...
78.3 percent (p=0.017) Blood pressure less than 130/80 mmHg: 54.2 percent vs. 32.5 percent (p=0.001) In the study ... World (RW) Glycemic Control and Medication Adherence among Patients with Type 2 Di... read more
Lexicon Pharmaceuticals' CEO Hosts 2013 Research and Development Day Conference (Transcript)
Also if you look at the amount of urinary glucose excretion, this is someone less than that’s been higher doses of canagliflozin ... end of the study both the lower and the higher dose of LX4211 are a... read more
Too deliciously ironic for words: Gary Null hoist with his own petard
But then I saw something even better: A controversial alternative health guru is suing ... nation’s leading promoters of dubious treatment for serious disease” – claims the manufacturer of Gary Null’s ... read more
Looking for another news?
Best Treatments for Type 2 Diabetes
And one study found that 47 percent ... the upper limit of normal, but less than the 126 mg/dL required for a diagnosis of diabetes. The most recent estimate from the Centers for Disease Control and P... read more
Zafgen, Inc. (ZFGN)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file repo... read more